EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis

Clara Cortell-Fuster, María Amparo Martínez-Gómez, Ana Cristina Cercós-Lleti, Mónica Climente-Martí, Tania Díaz-Corpas, Almudena Mateu-Puchades, Ángeles Revert-Fernández

Farmacia Hospitalaria · 2025

DOI: 10.1016/j.farma.2024.04.023 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2025. Verfasst von Clara Cortell-Fuster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: cortell_cla@gva.es. Hauptthemen laut MEDLINE: Sirolimus, Angiofibroma, Tuberous Sclerosis, Facial Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service: rapamycin 0.4% liposomal formulation, with better organoleptic characteristics and a more favorable release profile of the active ingredient. The purpose of this study is to evaluate the effectiveness and safety of liposomal topical rapamycin for the treatment of facial injuries in this rare disease. METHOD: This was an observational, prospective, and multicenter study. Effectiveness was evaluated mainly through facial angiofibroma severity index (FASI), investigator's global assessment (IGA) scores, and dermatology life quality index (DLQI) questionnaire. To assess the safety profile of rapamycin, adverse reactions were reported, and blood tests and blood rapamycin levels were performed during treatment. RESULTS: Eleven patients were included, of which 8/11 (73%) patients obtained successful treatment according to FASI and IGA scores after 24 weeks of treatment. Statistical analysis demonstrated a significant improvement (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusAngiofibromaTuberous SclerosisFacial NeoplasmsAntibiotics, AntineoplasticHumansMaleFemaleLiposomesProspective StudiesAdultYoung AdultTreatment OutcomeAdolescentQuality of LifeMiddle Aged

Stichwörter der Autor:innen

Angiofibromas facialesEsclerosis tuberosaFacial angiofibromasFormulaciónFormulationLiposomasLiposomesRapamicinaRapamycinSirolimusSirólimusTuberous sclerosis

Substanzen

SirolimusLiposomesAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain. Electronic address: cortell_cla@gva.es.
  • Servicio de Farmacia, Hospital Universitario Doctor Peset, Valencia, Spain.
  • Servicio de Dermatología, Hospital Universitario Doctor Peset, Valencia, Spain.
  • Servicio de Dermatología, Hospital Clínico Universitario, Valencia, Spain.

Zitieren

APA

Cortell-Fuster, C., Martínez-Gómez, M. A., Cercós-Lleti, A. C., Climente-Martí, M., Díaz-Corpas, T., Mateu-Puchades, A., & Revert-Fernández, Á. (2025). Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2024.04.023

Vancouver

Cortell-Fuster C, Martínez-Gómez MA, Cercós-Lleti AC, Climente-Martí M, Díaz-Corpas T, Mateu-Puchades A, et al. Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis. Farmacia Hospitalaria. 2025. doi:10.1016/j.farma.2024.04.023

BibTeX
@article{CortellFuster2025,
  author = {Cortell-Fuster, Clara and Martínez-Gómez, María Amparo and Cercós-Lleti, Ana Cristina and Climente-Martí, Mónica and Díaz-Corpas, Tania and Mateu-Puchades, Almudena and Revert-Fernández, Ángeles},
  title = {Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis},
  journal = {Farmacia Hospitalaria},
  year = {2025},
  doi = {10.1016/j.farma.2024.04.023}
}
Kostenlos starten →